Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study of AL8326 in Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: AL8326 tablets
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT06794957
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medicaal University, Bengbu, Anhui, China
🇨🇳Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Xuancheng People´s Hospital, Xuancheng, Anhui, China
Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
- Conditions
- Sarcoma,Soft TissueGynecologic Cancer
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Advenchen Laboratories, LLC
- Registration Number
- NCT05612191
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- Conditions
- Alveolar Soft Part SarcomaSynovial SarcomaSoft-Tissue SarcomaLeiomyosarcoma
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 325
- Registration Number
- NCT03016819
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
- Conditions
- Fallopian Tube CarcinomaCervical CarcinomaEndometrial CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 294
- Registration Number
- NCT02584478
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Long Beach, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Baptist Health Lexington Oncology Research, Lexington, Kentucky, United States
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
- Conditions
- Endometrial CancerOvarian CancerCervical Cancer
- Interventions
- Drug: AL3818
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02558348
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States